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Abstract
Aurora-A is a serine/threonine protein kinase and plays an important role in the control of mitotic progression. Dysregulated
expression of Aurora-A impairs centrosome separation and maturation, which lead to disrupted cell cycle progression and
tumorigenesis. However, the molecular mechanism by which Aurora-A causes cell malignant transformation remains to be
further defined. In this report, using transcription factors array and mRNA expression profiling array, we found that
overexpression of Aurora-A suppressed transcription activity of AP-2a, a tumor suppressor that is often downregulated in
variety of tumors, and inhibited expression of AP-2a-regulated downstream genes. These array-based observations were
further confirmed by microwell colorimetric TF assay and luciferase reporter assay. Downregulated transcription activity of
AP-2a by Aurora-A was found to be associated with reduced AP-2a protein stability, which appeared to be mediated by
Aurora-A enhanced ubiquitin-dependent proteasomal degradation of AP-2a protein. Interestingly, Aurora-A-mediated AP-
2a degradation was likely dependent Aurora-A kinase activity since inhibition of Aurora-A kinase activity was able to rescue
Aurora-A-induced degradation of AP-2a. Moreover, we defined a physical interaction between Aurora-A and AP-2a, and
such interaction might bridge the suppressive effect of Aurora-A on AP-2a protein stability. These findings provide new
insights into molecular mechanism by which Aurora-A acts as an oncogenic molecule in tumor occurrence and malignant
development.
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Introduction
Aurora-A is an important member of Aurora kinase family that
includes Aurora-A, Aurora-B and Aurora-C. This serine/threonine
protein kinase family plays critical roles in the control of centrosome
separation, bipolar spindle assembly, chromosome segregation and
cytokinesis[1,2,3]. Human Aurora-A locates on chromosome
20q13, a region that is frequently amplified in primary breast
tumors, colorectal cancers, ovarian cancers, neuroblastoma and
multiple cancer cell lines[4,5]. A number of investigations
demonstrate that Aurora-A is overexpressed in human esophageal
squamous cell carcinoma (ESCC). Overexpression of Aurora-A is
associated with poor differentiation and malignant status of clinical
ESCC. Levels of Aurora-A protein are correlated to the migrating
potentials of tumor cells[6]. In addition, Aurora-A promotes cancer
cell proliferation and inhibits cisplatin- or UV-induced apoptosis,
probably through its up-regulation of Bcl-2 expression[7]. These
observations strongly suggest that Aurora-A is dysregulated in
human ESCC and plays an important role in the development of
ESCC although further investigations are required for elucidating
the underlying mechanism.
Members of AP-2 transcription factor family contain a DNA
binding domain at the C-terminus and an activation domain at N-
terminus. AP-2a is the first identified AP-2 family member, which
binds to a typical consensus sequence (59-GCCNNNGGC-39)a s
homodimers or heterodimers and regulates the gene expression.
AP-2a is greatly involved in the control of cell proliferation and
differentiation[8,9], cell cycle progression[10,11] and apopto-
sis[12]. Multiple evidence indicate that AP-2a acts as a tumor-
suppressor gene. Reduced expression of AP-2a is often detected in
several types of cancer, such as breast cancer, cutaneous malignant
melanoma, prostatic carcinoma, neuroglioma [13-17], indicating
that loss of AP-2a function may contribute to tumorigenesis and
development of tumor malignancy.
To elucidate the molecular mechanism of Aurora-A in the
occurrence and development of ESCC, we attempted to
investigate the regulatory roleso fA u r o r a - Ai nt h ec o n t r o lo f
global gene expression. We utilized two high-throughput
methodologies: the mRNA expression profiling array and
oligonucleotide array-based transcription factors assay to
analyze the effect of Aurora-A on gene transcription. We found
that in cells expressing high Aurora-A, AP-2a transcription
activity was down regulated, which was coupled with downreg-
ulation of AP-2a-regulated downstream genes. Furthermore, we
observed that Aurora-A was able to interact with AP-2a and
decrease AP-2a protein stability by promoting proteasome
mediated protein degradation. These findings demonstrate the
functional connection between Aurora-A and AP-2a and the
PLoS ONE | www.plosone.org 1 August 2011 | Volume 6 | Issue 8 | e23110suppressing role of Aurora-A in the control of AP-2a-mediated
transcription.
Materials and Methods
1. Cell cultures, transfection and treatment
Human ESCC KYSE150 and ESCC EC9706 cell lines, which
were generously provided by Dr Shimada in Kyoto University,
were grown in RPMI 1640 (Invitrogen) supplemented with 10%
fetal bovine serum, 100 U/ml penicillin and 100 mg/ml strepto-
mycin, maintained at 37uC humidified atmosphere of 5% carbon
dioxide. pEGFP-Aurora-A transfected KYSE150 cells and Auro-
ra-A siRNA transfected EC9706 cells were cultured in the
presence of 400 mg/ml of G418 (Geneticin sulfate, GIBCO).
HCT116 p53
+/+ and HCT116 p53
-/- cells (gifts from Dr. Bert
Vogelstein, Johns Hopkins University) were grown in DMEM
supplemented with 10% FBS. For cell transfection, KYSE150/
GFP-Aurora-A and KYSE150/GFP cells, which were stable cell
lines through stable transfection of pEGFP-Aurora-A or pEGFP
empty vector in human ESCC KYSE150 cells[7], were seeded
onto 96-well plates one day prior to transfection. In each well,
0.1 mg of DNA and 0.25 ml of Lipofectamine2000 (Invitrogen)
were added to 50 ml of RPMI 1640 (Invitrogen). Fresh medium
was added at 6 h after transfection, and cells were harvested 48 h
later. For analysis of protein stability, 100 mg/ml CHX (cyclohex-
imide) (Sigma–Aldrich Corp., St. Louis, MO) or 10 mmol/L
MG132 (Sigma–Aldrich Corp., St. Louis, MO) was added to cell
medium, and then cells were harvested at the indicated time
points. The Aurora-A kinase inhibitor III (Merck Calbiochem Inc.
Darmstadt, Germany, 189405) dissolved in DMSO and stored at
50 mg/ml at 220uC, was used at 1 mM for 2 h prior to treatment
with CHX.
2. Gene expression profiling array analyses
Total RNAs from the KYSE150/GFP-Aurora-A and
KYSE150/GFP cell lines were extracted using Trizol reagent
according to the manufacturer’s instructions (Invitrogen). The
RNA (5 mg) was used to produce a KIENOW-labeled cDNA
probe for hybridization of a expression array, which contain
21,571 probes (CapitalBio Corporation, Beijing, China), and
analyzed using a LuxScan10 K/A laser scanner (CapitalBio
Corporation, Beijing, China). The results were imported into
GenePix Pro4.0 software (Axon instrument company) for data
mining. Statistical comparisons were made using Student’s t test by
the SPSS software. A significant difference was defined as
P,0.05[19].
3. Single Primer Amplification assisted Oligonucleotide
array-based transcription factor assay (SPA-OATFA)
We performed transcription factor assays based on oligonucle-
otide arrays. Nuclear extracts were prepared by nuclear extraction
kit (Active Motif, Carlsbad, CA), the single primer amplification
(SPA) and the array hybridization was performed using oligonu-
cleotide array-based transcription factor assay (OATFA) according
to the manufacturer’s instructions as described previously
(CapitalBio Corporation, Beijing, China) [20,21].
4. Nucleoprotein extraction and Western Blot analysis
Cells were harvested, rinsed with PBS and nuclear extracts were
prepared by NE-PER nuclear and cytoplasmic extraction Kit
(Pierce, Rockford, IL). 100 mg of proteins were used for
electrophoresis 10% SDS–PAGE. After electrophoresis, the
proteins were transferred to nitrocellulose membranes. Mem-
branes were blocked in 5% milk, washed with PBST (PBS with
0.1% Tween), and incubated with anti-Aurora-A (Cell Signaling,
Beverly, MA, 3092), AP-2a (Santa Cruz Biotechnology, Santa
Cruz, CA, sc-12726), and actin antibodies (Santa Cruz Biotech-
nology, Santa Cruz, CA, sc-8532). Following washing and
incubation with horseradish peroxidase-conjugated anti-rabbit or
anti-mouse antibody at 1:3000 in 5% milk, the membranes were
washed and detected by ECL (Applygen Technologies Inc.,
Beijing, China) and exposure to x-ray film[22].
5. Microwell colorimetric TF assay (ELISA)
Microwell colorimetric TF assay was performed as reported by
Renard et al[23]. Nuclear proteins from the KYSE150/GFP-
Aurora-A and KYSE150/GFP cell lines were incubated with AP-
2a binding DNA double-stranded oligonucleotidic probe on multi-
well plates and the AP-2a antibody was added. Subsequently, the
peroxidase-conjugated anti-mouse IgG was bound to the anti-AP-
2a antibodies. After coloration for 15 min, the absorbance of each
well was measured at 450 nm with an ultramark microplate reader
(Bio-Rad, Hercules, CA). Lysis buffer was incubated in the
microwells instead of nuclear proteins as blank, and the results
were calculated after subtraction of the blank values.
6. Luciferase assays
The (AP-2)3-TK-LUC expression vector was a gift from Dr
Carlo M. Croce of Ohio State University[24]. Three repeats of the
AP-2–binding site were cloned upstream of the basic promoter of
thymidine kinase (TK) in the pGL3 (Promega, Madison, WI).
KYSE150/GFP-Aurora-A and KYSE150/GFP cells were tran-
siently transfected with AP2-LUC. To normalize for transfection
efficiency, cells were cotransfected with pRL- SV40 expression
vector (Luciferase Assay System, Promega). All transfection assays
contained 100 ng of reporter plasmid and 1.0 ng of pRL-SV40
plasmid. Meanwhile, the cells were cotransfected with empty
pGL3-Basic vector and pRL-SV40 as controls. Cells were
collected 48 hours later, rinsed with PBS, resuspended in reporter
cell lysis buffer (Promega, Madison, WI), and incubated for 15
minutes at room temperature. Insoluble material was spun down,
and luciferase activity was quantified according to the manufac-
turer’s protocol of the luciferase assay kit (Promega, Madison, WI).
Results were shown as fold induction of the luciferase activity read
by the manual luminometer (TD-20/20
n; Turner Designs,
Sunnyvale, CA) compared with control cells. Differences were
determined by t-test, and P,0.05 was considered significant.
7. Immunoprecipitation
For immunoprecipitation, 1 mg of cellular protein was first
incubated with 7.5 mg of the indicated anti-Aurora-A, AP-2a
antibodies for 6 h at 4uC and further incubated overnight at 4uC
after addition of 10 ml of protein A/G-agarose beads (Santa Cruz
Biotechnology, Santa Cruz, CA). Immunoprecipitates were
washed six times with lysis buffer and loaded onto SDS-PAGE
gel and transferred to nitrocellulose membranes for immunoblot-
ting analysis[25].
8. GST pull-down assays
GST pull-down assays were performed with recombinant
Aurora-A-GST protein and GST protein alone expressed in E.
coli. GST fusion protein and GST protein were bound to 15 ml
glutathione-sepharose beads for 6 h at 4uC. The sepharose beads
were then incubated with a mixture of protein extraction for 6 h at
4uC with gentle rotation. After being washed with lysis buffer for
3–5 times gently, the beads incubated were boiled in SDS–PAGE
loading buffer and analyzed by Western Blot assay.
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1. Transcription activity of AP-2a is downregulated by
Aurora-A
In spite of the understanding on the roles of Aurora-A in the mitotic
progression, little is know about its effect on transcriptional regulation.
Therefore,the single primer amplification assisted oligonucleotide
array-based transcription factor assay (SPA-OATFA) was employed
to characterize transcriptional factors that might be regulated by
Aurora-A. Using such TF array that contains total 240 transcription
factors, we first compared activities of global transcription factors in
both cells expressing high levels of Aurora-A (KYSE150/GFP-Aurora-
A) and control cell line (KYSE150/GFP). As shown in Figure 1A and
1B, 5 transcription factors (AP-1, NF-E2, GATA, NFKB, C/EBP)
exhibited up-regulated transcription activities, but 4 transcription
factors (MYC/MAX, FOXD1, AP-2 and CDP) showed significant
downregulation of their transcription activity in KYSE150/GFP-
Aurora-A cells. These data suggest that overexpression of Aurora-A
might affect activities of a group of important transcription factors.
Since AP-2a (TFAP2A) is often downregulated in human cancers and
acts as a tumor-suppressor gene [14–17], the further efforts were es-
pecially made in understanding how AP-2a is regulated by Aurora-A.
Meanwhile, we carried out analysis of mRNA expression
profiling to search for the genes regulated by Aurora-A. This
mRNA expression array included 21,571 genes of human genome.
Totally, 209 differentially expressed genes were identified in
KYSE150/GFP-Aurora-A compared to KYSE150/GFP cells,
including 129 up-regulated genes (cut off .2.0) and 80 down-
regulated genes (cut off ,0.5). In support of the observations that
Aurora-A suppresses AP-2a activity, we found that a group of AP-
2a-regulated genes, including ERBB2[26], KRT17[27],
ESR1[28,29], KRT14[30]were significantly downregulated when
cells express high level of Aurora-A (Figure 1C). HSF1 and CASP7
were not the AP-2a-regulated genes, and the expression was not
affected by Aurora-A overexpression.
Usually, using SPA-OATFA as the first stage screening tool,
researchers can rapidly select potential candidate. However,
further antibody-based methods should be performed to validate
the SPA-OATFA data. We first utilized the microwell colorimetric
TF assay to verify the SPA-OATFA results. Following binding of
the double-stranded oligonucleotidic probes on multi-well plates,
nuclear extracts were added to the microwells and incubation with
mouse anti-AP-2a antibodies. Subsequently the peroxidase-
conjugated anti-mouse IgG was bound to the anti- AP-2a
antibodies. Finally, the absorbance of each well was measured,
which reflects AP-2a protein activity. Consistent with the
observations in SPA-OATFA assay, AP-2a activity was obviously
downregulated in the KYSE150/GFP-Aurora-A compared to the
KYSE150/GFP (Figure 1D).
We also employed the reporter gene assay to determine the
influence of Aurora-A on AP-2a activity. The KYSE150/GFP-
Aurora-A and KYSE150/GFP cells were transiently transfected
with AP2-LUC plasmid, a luciferase reporter cloned downstream of
TFAP2-binding elements. To normalize the transfection efficien-
cy, cells were cotransfected with pRL-SV40 expression vector.
Luciferase activity was quantified using a luminometer. Results
were shown as fold induction of the luciferase activity. Clearly, AP-
2a activity was downregulated in the KYSE150/GFP-Aurora-A
cells compared to the KYSE150/GFP (Figure 1E).
2. Aurora-A downregulates AP-2a protein expression in a
p53-independent manner
It is well accepted that activity of transcription factors is closely
related to their protein levels and protein modifications. We
further examined the effect of Aurora-A on the protein level of AP-
2a. Total cellular proteins were prepared from KYSE150/GFP-
Aurora-A and KYSE150/GFP cells and subjected to immuno-
blotting assay with AP-2a antibody. As shown in Figure 2A, AP-2a
protein levels were much lower in KYSE150/GFP-Aurora-A than
that seen in KYSE150/GFP cells. Additionally, siRNA approach
was used to confirm suppressive effect of Aurora-A on AP-2a.
Following knockdown of endogenous of Aurora-A in EC9706/
pGCsi-Aurora-A cells, AP-2a protein expression was clearly up
regulated in contrast to the control cells (EC9706/pGCsi)
(Figure 2B). These results indicate that Aurora-A is able to affect
AP-2a protein level, which contributes to downregulation of AP-
2a transcription activity.
Previous studies have demonstrated that phosphorylation by
Aurora-A induces MDM2-mediated destabilization and inhibition
of tumor suppressor p53, and in turn results in abrogation of p53
DNA binding and transactivation[31,32]. In addition, Li et al have
reported that AP-2a is a transcriptional target of p53[33]. So the
question raised here is whether Aurora-A downregulation of AP-
2a is correlated to Aurora-A inhibition on p53. To confirm this
hypothesis, HCT116 p53
+/+ and HCT116 p53
-/- cells (a somatic
knock-out for p53 derived from HCT116 cell line, gifts from Dr.
Bert Vogelstein, Johns Hopkins University) were transfected with
pEGFP-Aurora-A and control plasmids. Following 48h of
incubation, we collected cellular proteins and examined the levels
of AP-2a in both cell lines. While, the downregulation of AP-2a
protein level was seen in both cell lines after introduction of
Aurora-A expression vector into cells (Figure 2C). Likely, Aurora-
A downregulates AP-2a protein level in a p53-independent
manner.
3. Overexpression of Aurora-A enhances the
proteasome-dependent degradation of AP-2a
Next, we further investigated biochemical mechanism(s) by
which Aurora-A downregulates AP-2a protein. We examined the
stability of AP-2a protein in both KYSE150/GFP-Aurora-A and
KYSE150/GFP cell lines treated with protein synthesis inhibitor
cycloheximide (CHX) for different time points (0, 1, 2, 4, 6 and
8 h). As shown in Figure 3A and 3B, in KYSE150/GFP cells, AP-
2a protein was stable with a long half-life, and protein level was
decreased only 20% after 8 h. In contrast, in Aurora-A
overexpression cells, the level of AP-2a was reduced more than
50% at 4 h after treatment with CHX, and its level was less than
20% after 6 h. These results suggest that Aurora-A overexpression
enhances the degradation of AP-2a.
It has been reported that the proteasomal-degradation pathway
controls the stability of AP-2a protein[34]. It is reasonable to
suspect that Aurora-A enhanced degradation of AP-2a might be
associated with the proteasomal-degradation pathway. Thus, both
KYSE150/GFP-Aurora-A and KYSE150/GFP cells were treated
with CHX alone or treated with CHX in the presence of MG132,
a selective inhibitor of the proteasome and followed by the analysis
of AP-2a protein levels via immunoblotting analysis. As shown in
Figure 3C, AP-2a protein was clearly accumulated in both cell
lines following treatment with MG132. These data suggest that the
effect of Aurora-A on AP-2a stability might be mediated through
activation of proteasome-dependent pathway.
4. Aurora-A enhanced AP-2a degradation depends on its
kinase activity
To investigate whether Aurora-A-induced AP-2a degradation
relies on Aurora-A kinase activity, KYSE150/GFP-Aurora-A cells
were treated with a specific inhibitor (Aurora-A kinase inhibitor
Aurora-A Regulation of AP-2a
PLoS ONE | www.plosone.org 3 August 2011 | Volume 6 | Issue 8 | e23110Figure 1. Transcription activity of AP-2a is downregulated by Aurora-A. (A) The summary of the transcription factors with significant
changes in their activities by transcription factors array when Aurora-A was overexpressed. (B) Fluorescence images of the transcription factors arrays
hybridized with nuclear extracts from KYSE150/GFP-Aurora-A and KYSE150/GFP cells. The analysis of arrays was replicated twice, exchanging the Cy3-
and Cy5- label. Magnified panels show the spots representing the activity of AP-2 transcription factor that was down-regulated upon Aurora-A
overexpression. (C) The summary of the AP-2a-regulated genes with significant down-expression when Aurora-A was overexpressed by mRNA
expression profiling array. The black bars represent the AP-2a-regulated genes, and the gray bars represent the genes which were not the AP-2a-
regulated genes. (D) The nucleoprotein extraction of KYSE150/GFP-Aurora-A and KYSE150/GFP cells were incubated with AP-2a binding DNA double-
stranded oligonucleotidic probe on multi-well plates, then anti-AP-2a antibodies and the peroxidase-conjugated anti-mouse IgG were subsequently
added. At last, the samples could be read for the colorimetric detection. (E) KYSE150/GFP-Aurora-A and KYSE150/GFP cells were cotransfected with
(AP-2)3-TK-LUC expression vector and a pRL-SV40 expression vector. Transcription activities were expressed as luciferase values after normalization.
All experiments were performed three times and described as mean 6 SD.
doi:10.1371/journal.pone.0023110.g001
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mainly dependent on its autophosphorylation of Thr288 in the
activation loop[35]. Thus, detection of Aurora-A autophosphory-
lation on Thr288 normally reflects its kinase activity. After
KYSE150/GFP-Aurora-A cells exposure to kinase inhibitor for
2 h, reduced Aurora-A autophosphorylation on Thr288 (p-
Aurora-A) was evidently detected (Figure 4A). Interestingly,
treatment with Aurora-A kinase inhibitor in KYSE150/GFP-
Aurora-A cells substantially rescued Aurora-A enhanced AP-2a
degradation. In the cells treated with CHX and DMSO,
significant reduction of AP-2a protein was seen at two hours,
and AP-2a remained only 20% at 6 h after treatment. However,
the cells treated with CHX and the Aurora-A kinase inhibitor III
exhibited no reduction of AP-2a at 2 or 4 h, and remained 80% of
AP-2a protein levels at 6 h posttreatment(Figure 4B, 4C). These
observations indicate that Aurora-A kinase activity is required for
its role in regulating AP-2a degradation.
5. Aurora-A physically interacts with AP-2a
Aurora-A has been shown to interact with multiple cellular
proteins in order to regulate their biological func-
tions[31,32,36,37]. Thus, we examined if enhanced AP-2a
degradation by Aurora-A might involve the physical interaction
between Aurora-A and AP-2a. To address this issue, protein
extracts isolated from KYSE150/GFP-Aurora-A cells were
incubated with anti-Aurora-A and anti-AP-2a antibodies respec-
tively, and then immunoprecipitated with protein A/G-agarose
beads. The immuno-complexes were analyzed by Western
Blotting assay, and the results were shown in Fig 5. Aurora-A
protein was presented in the immunocomplexes precipitated by
the antibodies against AP-2a (Figure 5A), and also AP-2a protein
was detected in the immuno-complexes precipitated by the
antibodies against Aurora-A (Figure 5B). In contrast, neither
Aurora-A nor AP-2a was detected in the precipitates with IgG
antibody (control), suggesting a physical interaction of Aurora-A
with AP-2a. To further verify Aurora-A interaction with AP-2a,
the Aurora-A–GST fusion protein and GST protein alone were
incubated with cell lysates. Similarly, AP-2a protein was seen in
the pull-down complex by Aurora-A–GST, but not in the complex
by GST protein (Figure 5C). Collectively, these results indicate
that there is a physical interaction between Aurora-A and AP-2a.
Discussion
Both of expression level and the kinase activity of Aurora
kinases are found to be up-regulated in several human cancers,
which are often companied by Aurora-A gene amplification[6,38].
Overexpression of Aurora-A promotes cancer cell proliferation
and xenograph tumor growth in nude mice[4,34]. The activity of
Aurora kinases is finely regulated, mainly by phosphorylation and
degradation. Aurora-A interacts with several tumor suppressor
proteins, including p53[31,32], BRCA1[37], Gadd45a[18]. Al-
though Aurora-A exhibits strong oncogenic property, the
molecular mechanism of how Aurora-A kinase plays a role in
tumorigenesis remains to be further defined.
Figure 2. Regulation of AP-2a gene expression by Aurora-A. (A)
AP-2a protein levels in KYSE150/GFP-Aurora-A and KYSE150/GFP cells
were analyzed using immunoblotting assay. The actin levels were
measured as loading control. (B) AP-2a protein levels in EC9706/
pGCsi???EC9706/pGCsi-Aurora-A cells were examined by Western
Blotting assay. (C) The HCT116 p53
+/+ and HCT116 p53
-/- cells were
transiently transfected with pEGFP-Aurora-A and control plasmids. Cells
were lysed after 48h of incubation and evaluated for the expression of
AP-2a by Western Blotting assay.
doi:10.1371/journal.pone.0023110.g002
Figure 3. Overexpression of Aurora-A enhances the degrada-
tion of AP-2a. (A) KYSE150/GFP-Aurora-A and KYSE150/GFP cells were
treated with CHX respectively, and then harvested at the indicated time
points. AP-2a protein level at each time point was determined by
Western Blot. (B) The amounts of AP-2a were calculated by
densitometry and normalized to corresponding actin levels. The column
diagram represents the amount of normalized AP-2a at each time point
comparing with the original levels (0 h). (C) Aurora-A enhances the
proteasome-dependent degradation of AP-2a. KYSE150/GFP-Aurora-A
and KYSE150/GFP cells were treated with CHX alone or combination
with MG-132. AP-2a protein level was determined by Western Blot.
doi:10.1371/journal.pone.0023110.g003
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promotes cell proliferation, invasion and metastasis and antago-
nizes apoptosis in ESCC cells[7]. To better understand how
Aurora-A functions as an oncogenic protein in the control of
important cellular processes, we carried out a series of experiments
to investigate the effect of Aurora-A on transcription regulation.
Through the expression profiling array and single primer
amplification assisted oligonucleotide array-based transcription
factors assay (SPA-OATFA), we found that a group of transcrip-
tion factors are possibly regulated by Aurora-A (Figure 1A).
Among these downregulated transcription factors, AP-2a was of
interest due to its tumor-suppressive function and frequent
downregulation in human cancers [14–17] and attracted our
attention for further detailed studies. Normally, activities of
transcription factors often include DNA-binding activity and
transcriptional activity. SPA-OATFA is a method for only
examining DNA-binding activity in vitro. Thus, in addition to
utilizing the microwell colorimetric TF assay to further verify the
SPA-OATFA results (Figure 1D), we also performed AP-2a
reporter gene assay to demonstrate that the transcriptional activity
of AP-2a was also down-regulated by Aurora-A (Figure 1E).
With regard to the mechanism by which Aurora-A suppresses
AP-2a transcription activity, it is demonstrated that Aurora-A
affects AP-2a proteins stability. In the analysis of AP-2a protein
level, we found that there was a great reduction of AP-2a protein
in cells expressing high level of Aurora-A (KYSE150/GFP-
Aurora-A cell line) compared with the control cells (KYSE150/
GFP cell line) (Figure 2A). These observations were further
confirmed in Aurora-A knockdown cells (EC9706/pGCsi-Aurora-
A), where endogenous Aurora-A was suppressed by Aurora-A
siRNA (Figure 2B). Interestingly, we demonstrated that overex-
pression of Aurora-A increased ubiquitin-dependent proteasomal
degradation of AP-2a protein, and treatment of cells with the MG-
132 greatly rescued the level of AP-2a protein in the presence of
overexpressed Aurora-A. Clearly, downregulations of AP-2a
transcription activity and protein stability by Aurora-A are
associated with Aurora-A kinase activity. Employment of a specific
kinase inhibitor of Aurora-A substantially showed a great rescue of
protein degradation of AP-2a by Aurora-A (Figure 4).
It has previously been reported that Aurora-A induced p53
degradation by phosphorylation of Ser-315[31] and that DNA
binding and transactivation activity of p53 were abrogated by
phosphorylation of Aurora-A[32]. Moreover, Li et al have
reported that the tumor suppressor activity of AP-2a is mediated
through a direct interaction with p53 and that AP-2a protein may
mediate some of the downstream effects of p53 expression[33].
However, when introducing Aurora-A expression vectors into
Figure 4. Aurora-A-mediated AP-2a degradation depends on
Aurora-A kinase activity. (A) KYSE150/GFP-Aurora-A cells were
exposed to 1 mM of Aurora-A kinase inhibitor and cellular proteins
were collected 2 hours later. Western Blot was performed with
antibodies to pThr288 on Aurora-A or total Aurora-A. DMSO was used
as a negative control. (B) KYSE150/GFP-Aurora-A cells were exposed to
Aurora-A kinase inhibitor or DMSO for 2 hours prior to treatment with
CHX. Cells were harvested at the indicated time points and analyzed by
Western Blot. (C) The amounts of AP-2a were calculated by
densitometry and normalized to corresponding actin levels. The column
diagram represents the amount of normalized AP-2a at each time point
comparing with the original levels (0 h).
doi:10.1371/journal.pone.0023110.g004
Figure 5. Physical association of Aurora-A with AP-2a. (A`B)
Protein extracts from KYSE150/GFP-Aurora-A cells were prepared and
immunoprecipitated with anti-Aurora-A, anti-AP-2a, mouse or rabbit
IgG. The immunocomplexes were analyzed by SDS-PAGE and immuno-
blotted with antibodies against Aurora-A and AP-2a respectively. The
visualized bands were shown for Aurora-A and AP-2a. (C) Aurora-A-GST
fusion protein was bound to glutathione-sepharose beads, and
incubated with protein extracts. The pull-down complexes were
analyzed by SDS-PAGE and immunoblotted with antibodies against
AP-2a. The visualized band of 48 kDa was AP-2a.
doi:10.1371/journal.pone.0023110.g005
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+/+ and HCT116 p53
-/- cells, we did not see
differential expression levels of AP-2a in these two cell lines with
different p53 status, and both cell lines exhibited similar reduction
of AP-2a protein (Figure 2C). These finding excludes the
involvement of p53 in Aurora-A-downregulation of AP-2a protein
level and transcription activity.
There are two main classes of transcription factors: one class is
‘‘constitutively active TFs’’ which are programmed to enter the
nucleus to take part in transcription after they are synthesized; the
another class is ‘‘regulatory TFs’’, whose localization and activities
are regulated by specific activation signals or modifications[39].
AP-2a normally localizes in the nuclues and exerts its transcrip-
tional activation. We indeed performed immunofluorecent assay
to determine whether Aurora-A affects AP-2a subcellular
localization and influences its regulation of the downstream target
genes. Surprisingly, AP-2a predominantly localized in nucleus in
both KYSE150/GFP-Aurora-A and KYSE150/GFP cells (data
not show). Thus it appears that overexpression of Aurora-A may
not affect AP-2a subcellular localization.
Aurora-A often exerts important functions via its physical and
functional interactions with many critical cellular proteins, such as
p53[31,32], cyclin-B1 [36], BRCA1[37], c-Myc[40]. Such inter-
actions lead to altered stability or function of those Aurora-A-
associating proteins. Similarly, using Co-IP and GST-pull-down
assays, we defined that there was an interaction between Aurora-A
and AP-2a, and such Aurora-A interaction with AP-2a might
contributes to Aurora-A-mediated AP-2a degradation.
Currently, the underlying machinery involved in Aurora-A-
enhanced AP-2a degradation still remains to be further investi-
gated. We suspect that Aurora-A may interfere with the ubiquitin-
mediated degradation of AP-2a in different ways. First of all,
Aurora-A overexpression might induce phosphorylation and
activation of some ligases in ubiquitin system, and then lead to
enhanced AP-2a degradation. Second, the physical interaction of
Aurora-A with AP-2a may alter the conformation of AP-2a, which
could facilitate the ligase and other factors to recognize and bind
to AP-2a. Third, Aurora-A could directly phosphorylates AP-2a
and then decreases its stability. Although a protein kinase A-
mediated phosphorylation at position 239 of AP-2a did not change
the stability of AP-2a protein[34,41], there are some other
phosphorylation sites need to be defined in the future and
phosphorylation of these sites may influence the stability of AP-2a
protein.
Over the past decade, Aurora-A has attracted great attentions in
the field of cancer biology due to its potent oncogenic property.
However, most of efforts have been focused on exploring its roles
in the control of cell cycle progression. Dysregulated expression of
Aurora abrogates centrosome maturation, chromosomal segrega-
tion and leads to genomic instability[42–44]. Thus, the findings
that Aurora-A downregulates AP-2a transcription activity and
protein expression provide new insights into understanding on
Aurora-A-mediated cell transformation and carcinogenesis.
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